US Foreign Bribery Investigations Ramp Up, With 'Carrot' For Cooperation
This article was originally published in PharmAsia News
Pilot program from the US Department of Justice reduces fines for companies that voluntarily disclose misconduct; focus of investigations is broadening from sales to suppliers.
You may also be interested in...
The company agreed to pay $233.9m to the US Department of Justice and $112m to the Securities and Exchange Commission to settle foreign bribery charges tied to South Korea, Vietnam and Greece.
One analyst that has been tracking Alexion’s delayed SEC filing believes that a former employee’s allegation of improper Soliris sales is unlikely to represent widespread fraud.
Stakeholders suggest a variety of USPTO and FDA actions that could help ensure patents do not improperly delay generic and biosimilar competition.